House Select Committee on Aging

House Select Committee on Aging
Name	House Select Committee on Aging
Type	Select committee
Chamber	United States House of Representatives
Formed	1977
Disbanded	1992
Jurisdiction	United States Congress select committee on elder policy and oversight
Chairpersons	Claude Pepper, Elizabeth Furse, Olver, John

House Select Committee on Aging

The House Select Committee on Aging was a temporary United States House of Representatives select committee established in 1977 to examine issues affecting older Americans, conduct investigations, and influence policy relating to health care, social services, and consumer protection for the elderly. Its work intersected with major federal programs and institutions such as Social Security (United States), Medicare (United States), Medicaid, Department of Health and Human Services, Administration on Aging (United States), and federal agencies charged with consumer protection and law enforcement. The committee held high-profile hearings, produced reports that shaped debates in the 95th United States Congress through the 102nd United States Congress, and connected legislative actors, advocacy organizations, and executive branch officials.

History and Establishment

Created during the 95th Congress amid rising public concern about elder fraud, health care costs, and retirement security, the committee was modeled on prior ad hoc inquiries such as congressional investigations during the Watergate scandal and the work of the House Committee on Ways and Means subcommittees. Founding figures included senior legislators with long records on aging policy like Claude Pepper and members who had worked on age discrimination and retirement issues in the Senate Special Committee on Aging (United States). The committee's establishment reflected bipartisan interest from members associated with regions like Florida, Massachusetts, Michigan, and Pennsylvania, and aligned with actions by Presidents such as Jimmy Carter and later Ronald Reagan who faced pressures over elder policy.

Jurisdiction and Mandate

Although a select committee without permanent legislative jurisdiction like standing panels such as the House Committee on Ways and Means or the House Committee on Energy and Commerce, the committee focused on oversight and investigation related to programs administered by the Social Security Administration, Centers for Medicare & Medicaid Services, and the Federal Trade Commission. Its mandate included examining prescription drug costs, nursing home quality overseen by the Department of Health and Human Services, pension solvency issues linked to the Pension Benefit Guaranty Corporation, consumer fraud often investigated alongside the Federal Bureau of Investigation, and access to services coordinated with the Administration on Aging (United States) and nonprofit groups such as AARP.

Major Investigations and Reports

The committee conducted inquiries into a range of topics that produced influential reports used by policymakers and advocates. High-profile investigations scrutinized pharmaceutical pricing involving firms like Pfizer, Johnson & Johnson, and Merck & Co.; nursing home standards that implicated chains and regulators including the Food and Drug Administration and state health departments; and widespread telemarketing and investment fraud that drew attention from the Federal Trade Commission and Securities and Exchange Commission. Reports highlighted by members referenced cases in cities such as Miami, Chicago, Los Angeles, and New York City, and informed litigation and regulatory action by entities including the Department of Justice and state attorneys general.

Legislative Impact and Policy Outcomes

Although not a standing committee with direct bill-markup authority, the select committee influenced legislation by informing chairs and members of standing panels such as the House Committee on Ways and Means, House Committee on Education and Labor, and the House Committee on Energy and Commerce. Its findings contributed to reforms in prescription drug reimbursement affecting the Medicare Modernization Act debates, amendments to enforcement provisions used by the Federal Trade Commission Act implementations, and support for programs funded under measures like the Older Americans Act reauthorizations. The committee's oversight shaped executive branch policies under administrations from Carter administration through George H. W. Bush and into the early years of the Bill Clinton era.

Membership and Leadership

Leadership included prominent members of Congress with elder-policy backgrounds, allies from groups such as AARP and policy centers like the Brookings Institution who provided testimony. Chairs and ranking members came from states with large senior populations including Florida, Arizona, and California, and intersected with legislators from committees such as House Appropriations Committee and House Judiciary Committee. Notable members worked closely with federal officials from the Social Security Administration, Centers for Medicare & Medicaid Services, and the Administration on Aging (United States), as well as outside experts from universities like Johns Hopkins University, Harvard University, and University of Michigan.

Public Outreach and Advocacy

The committee amplified the voices of advocacy organizations and service providers including AARP, the National Council on Aging, the American Association of Retired Persons (AARP) affiliates, and state agencies. Hearings in cities such as Boston, Detroit, Philadelphia, and San Francisco drew testimony from representatives of hospitals like Mayo Clinic and advocacy groups like Catholic Charities USA. The committee worked with media outlets including The New York Times, The Washington Post, CBS News, and NBC News to publicize findings, and coordinated with think tanks such as the Urban Institute and American Enterprise Institute for policy analysis.

Criticisms and Controversies

Critics argued the select committee duplicated work of the Senate Special Committee on Aging and existing House standing committees, provoking debates in the House Republican Conference and House Democratic Caucus over resources and mandate. Some investigations led to disputes with industry groups like Pharmaceutical Research and Manufacturers of America and trade associations representing nursing homes, prompting legal challenges and public relations campaigns involving firms headquartered in New Jersey and New York. Allegations of partisanship surfaced during contentious hearings in the context of broader debates tied to the 1980 United States presidential election and later budget battles during the 1990s deficit debates.

Category:United States House of Representatives select committees